499 assets in Hepatocellular Carcinoma

Therapeutic assets addressing Hepatocellular Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Lobaplatin Hepatocellular Carcinoma	Zhujiang Hospital	P3	B (62)
Losartan Hepatocellular Carcinoma	Second Affiliated Hospital of Xi'an Jiaotong University	P4	B (62)
Pentapeptide-1 Hepatocellular Carcinoma	Second Affiliated Hospital of Soochow University	P3	B (62)
Regorafenib Hepatocellular Carcinoma	University of Miami	P3	B (62)
Serplulimab Hepatocellular Carcinoma	Shanghai Henlius Biotech	P3	B (62)
Shr-8068 Hepatocellular Carcinoma	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P3	B (62)
Tirelizumab Hepatocellular Carcinoma	Chen Xiaoping	P4	B (62)
Volitinib Hepatocellular Carcinoma	AstraZeneca	P3	B (62)
Warfarin Hepatocellular Carcinoma	Mansoura University	P4	B (62)
Apsolol Hepatocellular Carcinoma	AHS Cancer Control Alberta	P4	B (61)
Cetuximab Hepatocellular Carcinoma	Sanofi	P2	B (61)
Denosumab Hepatocellular Carcinoma	Tongji Hospital	P3	B (61)
Enoxaparin Hepatocellular Carcinoma	Mansoura University	P4	B (61)
Entecavir Hepatocellular Carcinoma	Sun Yat-sen University	P4	B (61)
Etoposide Hepatocellular Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P3	B (61)
Thalidomide Hepatocellular Carcinoma	Shanghai Zhongshan Hospital	P3	B (61)
2-CHLORO-N6-(3-IODOBENZYL)ADENOSINE-5'-N-METHYLURONAMIDE Hepatocellular Carcinoma	Can-Fite BioPharma	P3	B (60)
Adebrelimab Hepatocellular Carcinoma	Third Affiliated Hospital, Sun Yat-Sen University	P3	B (60)
Anlotinib Hydrochloride Capsules Hepatocellular Carcinoma	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P3	B (60)
Benmelstobart Hepatocellular Carcinoma	Nanfang Hospital, Southern Medical University	P3	B (60)
Capecitabine Hepatocellular Carcinoma	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	P3	B (60)
Durvalumab Hepatocellular Carcinoma	Amit Mahipal	P3	B (60)
Finotonlimab Hepatocellular Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P2/3	B (60)
Hydroxychloroquine Hepatocellular Carcinoma	VA Office of Research and Development	P2	B (60)
Pegargiminase Hepatocellular Carcinoma	Chang Gung Memorial Hospital	P3	B (60)
Pegylated-Interferon .Alfa. 2B (Peg-Ifn) Hepatocellular Carcinoma	Ningbo No.2 Hospital	P3	B (60)
Propofol Hepatocellular Carcinoma	Iuliu Hatieganu University of Medicine and Pharmacy	P4	B (60)
Raltitrexed Hepatocellular Carcinoma	Zhujiang Hospital	P3	B (60)
Tas-102 Hepatocellular Carcinoma	Symphogen A/S	P3	B (60)
Tenofovir Disoproxil Fumarate Hepatocellular Carcinoma	Ningbo No.2 Hospital	P4	B (60)
Vincristine Sulfate Hepatocellular Carcinoma	Children's Oncology Group	P3	B (60)
Biejia-Ruangan Compound Hepatocellular Carcinoma	Nanfang Hospital, Southern Medical University	P4	B (59)
Docetaxel Hepatocellular Carcinoma	Merck Sharp & Dohme LLC	P3	B (59)
Fludarabine Hepatocellular Carcinoma	Roswell Park Cancer Institute	P2	B (59)
hlx13 Hepatocellular Carcinoma	Shanghai Henlius Biotech	P3	B (59)
Immuncell-Lc Hepatocellular Carcinoma	GC Cell Corporation	P3	B (59)
Relatlimab Hepatocellular Carcinoma	Bristol-Myers Squibb	P2	B (59)
Vitamin D Hepatocellular Carcinoma	Taoyuan General Hospital	P4	B (59)
Axitinib Hepatocellular Carcinoma	University of Texas Southwestern Medical Center	P2	B (58)
Fludeoxyglucose Hepatocellular Carcinoma	National Cancer Institute (NCI)	P3	B (58)
Immunoglobulin G4 [234-Proline], Anti-(Human Protein Garp-Transforming Growth Factor ?1 Complex) (Human Monoclonal Abbv-151 ?4-Chain), Disulfide With Human Monoclonal Abbv-151 ?-Chain, Dimer Hepatocellular Carcinoma	AbbVie	P2/3	B (58)
Indocyanine Green Hepatocellular Carcinoma	University of Florida	P2	B (58)
Lenalidomide Hepatocellular Carcinoma	Shunda Du	P2	B (58)
Mesna Hepatocellular Carcinoma	St. Jude Children's Research Hospital	P2	B (58)
Mitoxantrone Hepatocellular Carcinoma	Fudan University	P2	B (58)
Obi 3424 Hepatocellular Carcinoma	Zhejiang Hisun Pharmaceutical Co. Ltd.	P2	B (58)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	B (58)
pf-08634404 Hepatocellular Carcinoma	Pfizer	P2	B (58)
Rituximab Hepatocellular Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	B (58)
Sapanisertib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	B (58)

Showing 51 to 100 of 499 assets

PreviousPage 2 of 10Next